Interleukin (IL)-12 is a key factor for inducing cellular immune responses, which play a central role in the eradication of cancer. In the present study, in order to create a dendritic cell (DC)-based vaccine capable of positively skewing immune response toward a cellular immunity-dominant state, we analyzed immunological characteristics and vaccine efficacy of DCs cotransduced with melanoma-associated antigen (gp100) and IL-12 gene (gp100 þ IL12/DCs) by using RGD fiber-mutant adenovirus vector (AdRGD), which enables highly efficient gene transduction into DCs. gp100 þ IL12/DCs could simultaneously express cytoplasmic gp100 and secretory IL-12 at levels comparable to DCs transduced with each gene alone. In comparison with DCs transduced with gp100 alone (gp100/DCs), upregulation of major histocompatibility complex class I, CD40, and CD86 molecules on the cell surface and more potent T-cell-stimulating ability for proliferation and interferon-g secretion were observed as characteristic changes in gp100 þ IL12/DCs. In addition, administration of gp100 þ IL12/DCs, which were prepared by a relatively low dose of AdRGD-IL12, could induce more potent tumor-specific cellular immunity in the murine B16BL6 melanoma model than vaccination with gp100/ DCs. However, antitumor effect and B16BL6-specific cytotoxic T-lymphocyte activity in mice vaccinated with gp100 þ IL12/DCs diminished with increasing AdRGD-IL12 dose during gene transduction, and paralleled the decrease in presentation levels via MHC class I molecules for antigen transduced with another AdRGD. Collectively, our results suggested that optimization of combined vector dose was required for development of a more efficacious DC-based vaccine for cancer immunotherapy, which relied on genetic engineering to simultaneously express tumor-associated antigen and IL-12.
D endritic cells (DCs) are potent professional antigenpresenting cells (APCs) that play a pivotal role in directing and amplifying the adaptive immune response to pathogens and infected/mutated cells. 1, 2 The ability of DCs to stimulate naive T cells has long been thought to be crucial in initiating an effective immune response, and DCs are uniquely situated at the interface between the innate and adaptive immune systems. Because of these immunological properties, DCs are currently under intense scrutiny as potential adjuvants for vaccines in many clinical settings. Studies in healthy volunteers and patients with cancer have shown that tumor-associated antigen (TAA)-pulsed DCs can boost both CD8 þ and CD4 þ T-cell responses in vivo. [3] [4] [5] Although these promising findings encourage the development of DC-based immunotherapy for cancer, the establishment of DC-manipulation capable of supplementing optimal vaccine function is required for the achievement of sufficient efficacy in current therapy. We previously established a highly efficient gene transduction technique into DCs by applying RGD fiber-mutant adenovirus vector (AdRGD), 6, 7 and demonstrated that DCs transduced with TAA gene using AdRGD are effective vaccine carriers for induction of tumor-specific immune responses in mice. 8, 9 These results suggested that the AdRGD system is very useful for DC-manipulation through transduction of genes encoding immunofunctional molecules as well as for antigen gene delivery into DCs.
The immune system is roughly classified into cellular immunity and humoral immunity, and optimal immune response is achieved by balanced activation of both systems. Cellular immune response, based on the activation of natural killer (NK) cells and TAA-specific cytotoxic T lymphocytes (CTLs), plays a more important role in elimination of tumor cells by tumor immunity than humoral immune response accompanied by antibody production from B cells. [10] [11] [12] [13] Therefore, an approach that biases immune balance toward the cellular immune response would enhance the efficacy of DC-based immunotherapy for cancer. Interleukin (IL)-12 is a 70 kDa (p70) heterodimer protein in which the 40 kDa (p40) and 35 kDa (p35) subunits are connected by one S-S bond.
14,15 IL-12 plays a key role in the induction of cellular immune responses, such as enhancement of proliferation and cytotoxic activity in NK cells and CTLs, 16, 17 production of interferon (IFN)-g from activated cells, [17] [18] [19] and promotion of differentiation of helper T-type 1 (Th1) cells from Th0 cells. 17, 20, 21 IFN-g is involved in IL-12-mediated tumor regression, 22 and IL-12 also exhibits an antiangiogenic effect that can account for some antitumor activity. 23 Thus, it was strongly predicted that DCs cotransduced with the TAA and IL-12 genes may be efficacious vaccine carriers that can drastically improve effectiveness of DC-based immunotherapy for cancer by positively biasing immune balance toward cellular immunity, the Th1-dominant state, by inducing IL-12 secretion as well as by sensitizing TAA-specific CTLs via TAA-peptide presentation on major histocompatibility complex (MHC) molecules.
In the present study, by using AdRGD, which is superior in gene transduction efficiency to DCs, we created a DC vaccine that simultaneously expressed gp100, a melanoma-associated antigen, and IL-12, and investigated its immunological characteristics and vaccine efficacy.
Materials and methods

Cell lines and mice
The helper cell line, 293 cells, was obtained from JCRB cell bank (Tokyo, Japan) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. CD8-OVA 1.3 cells, 24 a specific T-T hybridoma against ovalbumin (OVA) þ H-2K b (kindly provided by Dr CV Harding; Department of Pathology, Case Western Reserve University, Cleveland, OH), were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 50 mM 2-mercaptoethanol (2-ME), and antibiotics. Murine melanoma B16BL6 cells (H-2 b ; JCRB cell bank) were grown in minimum essential medium supplemented with 7.5% FBS and antibiotics. EL4 cells, a T-lymphoma cell line of C57BL/6 origin, and YAC-1 cells, a lymphoma cell line highly sensitive to NK cells, were purchased from ATCC (Manassas, VA) and maintained in RPMI 1640 medium supplemented with 10% FBS, 50 mM 2-ME, and antibiotics. Female C57BL/6 mice (H-2 b ) and female BALB/c mice (H-2 d ), ages 7-8 weeks, were purchased from SLC Inc. (Hamamatsu, Japan). All mice were held under specific pathogen-free conditions and the experimental procedures were in accordance with the Osaka University guidelines for the welfare of animals in experimental neoplasia.
Vectors
Replication-deficient AdRGD was based on the adenovirus serotype 5 backbone with deletions of regions E1 and E3. The RGD sequence for av-integrin-targeting was inserted into the HI loop of the fiber knob using a twostep method as previously described. 25 AdRGD-IL12, 26 AdRGD-gp100, 7 AdRGD-OVA, 8 and AdRGD-Luc were previously constructed by an improved in vitro ligation method, 25, 27, 28 and encoded the murine IL-12 gene derived from mIL12 BIA/pBluescript II KS(-) (kindly provided by Dr H Yamamoto; Department of Immunology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan), the human gp100 gene derived from pAx1-CA h-gp100 (kindly provided by Dr H Hamada; Department of Molecular Medicine, Sapporo Medical University, Sapporo, Japan), the OVA gene derived from pAc-neo-OVA (kindly provided by Dr MJ Bevan; Department of Immunology, Howard Hughes Medical Institute, University of Washington, Seattle, WA), and the luciferase gene derived from pGL3-Control (Promega, Madison, WI), respectively. All recombinant AdRGDs were propagated in 293 cells, purified by two rounds of cesium chloride gradient ultracentrifugation, dialyzed, and stored at À801C. Titers of infective AdRGD particles were evaluated by the end point dilution method using 293 cells.
Generation and viral transduction of DCs
DCs were prepared according to the method of Lutz et al 29 with slight modification. Briefly, bone marrow cells flushed from the femurs and tibias of C57BL/6 mice were seeded at 0.5-1 Â 10 7 cells per sterile 100-mm bacterial grade culture dish in 10 ml of RPMI 1640 containing 10% FBS, 40 ng/ml recombinant murine granulocyte/macrophage colony-stimulating factor (GM-CSF; kindly provided by KIRIN Brewery Co., LTD, Tokyo, Japan), 50 mM 2-ME, and antibiotics. On day 3, another 10 ml of culture medium was added to the dish for medium replenishment. On day 6, 10 ml of the culture supernatant was collected and centrifuged at 1500 rpm for 5 minutes at room temperature, and the pellet was resuspended in 10 ml of fresh culture medium, and then returned to the original dish to conserve unattached cells. On day 8, nonadherent cells were harvested and used as immature DCs. DCs cultured for another 24 hours with media containing 1 mg/ml lipopolysaccharide (LPS; Nacalai Tesque, Inc., Kyoto, Japan) were used as phenotypically mature DCs (LPS/DCs). In transduction using AdRGDs, DCs were suspended at a concentration of 5 Â 10 6 cells/ml in FBS-free RPMI 1640 and placed in a 15-ml conical tube. Each AdRGD was added at various multiplicity of infections (MOIs), the suspension was mixed well, and the tube was incubated at 371C for 2 hours with occasional gentle agitation. The cells were washed three times with phosphate-buffered saline (PBS) and resuspended in a suitable solution for subsequent experiments.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis
Transduced DCs and mock DCs were cultured on 100-mm bacterial grade culture dishes in GM-CSF-free culture medium for 24 hours. Total RNA was isolated from these cells and LPS/DCs using Sepasol-RNA I Super (Nacalai Tesque, Inc.) according to the manufacturer's instructions. RT proceeded for 60 minutes at 421C in a 50 ml reaction mixture containing 5 mg total RNA treated with DNase I, 10 ml 5 Â RT buffer, 5 mM MgCl 2 , 1 mM dNTP mix, 1 mM random primer (9-mer), 1 mM oligo(dT) 20 , and 100 U ReverTra Ace (TOYOBO Co., LTD, Osaka, Japan). PCR amplification of the gp100, IL12p35, IL-12p40, and b-actin transcripts was performed in 50 ml of a reaction mixture containing 1 ml of RTmaterial, 5 ml 10 Â PCR buffer, 1.25 U Taq DNA polymerase (TOYOBO Co., LTD), 1.5 mM MgCl 2 , 0.2 mM dNTP, and 0.4 mM primers. The sequences of the specific primers were as follows: human gp100: forward, 5 0 -tgg aac agg cag ctg tat cc-3 0 ; reverse, 5 0 -cct aga act tgc cag tat tgg c-3 0 ; murine IL-12p35: forward, 5 0 -tgt tta cca ctg gaa cta cac aag a-3 0 ; reverse, 5 0 -aga gct tca ttt tca ctc tgt aag g-3 0 ; murine IL-12p40: forward, 5 0 -ctc acc tgt gac acg cct ga-3 0 ; reverse, 5 0 -cag gac act gaa tac ttc tc-3 0 ; murine b-actin: forward, 5 0 -tgt gat ggt ggg aat ggg tca g-3 0 ; reverse, 5 0 -ttt gat gtc acg cac gat ttc c-3 0 . After denaturation for 2 minutes at 951C, 20 cycles of denaturation for 30 seconds at 951C, annealing for 30 seconds at 481C (for IL-12p40), 581C (for IL-12p35), or 601C (for gp100 and b-actin), and extension for 30 seconds at 721C were repeated and followed by completion for 4 minutes at 721C. The PCR product was electrophoresed on a 3% agarose gel, stained with ethidium bromide, and visualized under ultraviolet radiation. EZ Load (BIO-RAD, Tokyo, Japan) was used as a 100 bp-molecular ruler. The expected PCR product sizes were 362 bp (gp100), 334 bp (IL-12p35), 431 bp (IL12p40), and 514 bp (b-actin).
Intracellular staining method for human gp100 protein in transduced DCs
Transduced DCs were cultured on 100-mm bacterial grade culture dishes in GM-CSF-free culture medium for 24 hours. Cells (1 Â 10 6 ) were fixed by incubation for 10 minutes in 2% paraformaldehyde, and then cell membranes were permeabilized by incubation for 5 minutes in 1% saponin. The cells were incubated with 100 ml staining buffer (PBS containing 0.1% bovine serum albumin and 0.01% NaN 3 ) containing the anti-FcgRII/III monoclonal antibody (mAb), 2.4G2 (rat IgG 2b,k ; BD Biosciences, San Jose, CA), to block nonspecific binding of the subsequently used mAbs. After 30 minutes, the cells were incubated for 60 minutes with 100 ml staining buffer containing the HMB50 mAb against human gp100 (mouse IgG 2a ; Neomarkers, Fremont, CA), and then resuspended in 100 ml staining buffer containing fluorescein isothiocyanate-conjugated anti-mouse Ig k (187.1; BD Biosciences). After incubation for 30 minutes, 30,000 events of the stained cells were analyzed for human gp100 protein expression by a FACScalibur flow cytometer using CellQuest software (BD Biosciences). Between all incubation steps, cells were washed three times with staining buffer.
Evaluation of IL-12 secretion level in transduced DCs
Transduced DCs, LPS/DCs, and mock DCs were cultured on 24-well plates at 5 Â 10 5 cells/500 ml in GM-CSF-free culture medium for 24 hours. The supernatants were collected and the IL-12 level was measured using a murine IL-12p40 ELISA KIT and a murine IL-12p70 ELISA KIT (Endogen, Rockford, IL).
Analysis of surface marker-expression
All immunoreagents used in this experiment were purchased from BD Biosciences. Transduced DCs, LPS/ DCs, and mock DCs were cultured on 100-mm bacterial grade culture dishes in GM-CSF-free culture medium for 24 hours. Cells (1 Â 10 6 ) in 100 ml staining buffer were incubated for 30 minutes on ice with the 2.4G2 mAb. Then, cells were resuspended in 100 ml staining buffer and incubated for 30 minutes on ice using the manufacturer's recommended amounts of biotinylated mAbs:
, and GL1 (anti-CD86). The cells were then resuspended in 100 ml staining buffer containing phycoerythrin-conjugated streptavidin at a 1:200 dilution, and nonspecific binding was measured using phycoerythrin-conjugated streptavidin alone. After incubation for 30 minutes on ice, 30,000 events of the stained cells were analyzed for surface phenotype by flow cytometry. Between all incubation steps, cells were washed three times with staining buffer.
Antigen-presentation assay C57BL/6 DCs were transduced with various combinations of AdRGD-OVA, AdRGD-IL12, and AdRGDLuc, and then seeded on a 96-well flat-bottom culture plate at a density of 1 Â 10 5 cells/well. These cells were cocultured with 1 Â 10 5 cells/well CD8-OVA 1.3 cells at 371C for 20 hours. The response of stimulated CD8-OVA 1.3 cells was assessed by determining the amount of IL-2 released into an aliquot of culture medium (100 ml) using a murine IL-2 ELISA KIT (Amersham Biosciences, Piscataway, NJ).
Mixed leukocyte reaction (MLR)
Three kinds of T cells, including allogeneic naive T cells from intact BALB/c mice, syngeneic naive T cells from intact C57BL/6 mice, and syngeneic gp100-primed T cells DC vaccine cotransduced with TAA and IL-12 N Okada et al from C57BL/6 mice immunized intradermally with 1 Â 10 6 DCs transduced with AdRGD-gp100 at 25 MOI 1 week earlier, were purified from the splenocytes of each mouse as nylon wool nonadherent cells, and were used as responder cells at 1 Â 10 5 cells/well in 96-well plates. Transduced DCs, LPS/DCs, or mock DCs (stimulator cells) were inactivated by 50 mg/ml mitomycin C (MMC) for 30 minutes and added to responder cells in varying cell numbers. Cells were cocultured in 100 ml RPMI 1640 supplemented with 10% FBS, 50 mM 2-ME, and antibiotics at 371C and 5% CO 2 for 3 days. Control wells contained either stimulator cells alone or responder cells alone. Cell cultures were pulsed with 5-bromo-2 0 -deoxyuridine (BrdU) during the last 18 hours, and then proliferation of responder cells was evaluated by Cell Proliferation ELISA, BrdU (Roche Diagnostics Co., Indianapolis, IN).
Analysis of Th1/Th2 cytokine secretion from syngeneic T cells stimulated by transduced DCs C57BL/6 naive T cells were purified from splenocytes as nylon wool nonadherent cells, and were used as responder cells at 5 Â 10 6 cells/well in 24-well plates. Transduced DCs (stimulator cells) were added to responder cells at 5 Â 10 5 cells/well. Cells were cocultured in 1 ml RPMI 1640 supplemented with 10% FBS, 50 mM 2-ME, 10 U/ml recombinant murine IL-2 (PeproTech EC LTD, London, England) and antibiotics at 371C and 5% CO 2 for 5 days. The supernatants were collected and the IFN-g, IL-4, and IL-10 levels were measured using a murine IFN-g ELISA KIT, a murine IL-4 ELISA KIT, and a murine IL-10 ELISA KIT (Biosource International, Camarillo, CA), respectively.
Tumor protection assay
Transduced DCs were intradermally injected into the left flank of C57BL/6 mice at 2 Â 10 5 cells/50 ml. At 1 week after the vaccination, 2 Â 10 5 B16BL6 melanoma cells were intradermally inoculated into the right flank of the mice. The major and minor axes of the tumor were measured using microcalipers, and the tumor volume was calculated by the following formula: (tumor volume; mm 3 ) ¼ (major axis; mm) Â (minor axis; mm) 2 Â 0.5236. The mice were euthanized when one of the two measurements was greater than 20 mm.
Europium (Eu)-release assay for cytolytic activity of NK cells and CTLs
Transduced or mock DCs were administered once intradermally into C57BL/6 mice at 2 Â 10 5 cells/50 ml. At 1 week after immunization, nonadherent splenocytes were prepared from these mice and directly used as NK effector cells. The splenocytes were restimulated in vitro using B16BL6 cells, which were cultured in media containing 100 U/ml recombinant murine IFN-g (PeproTech EC LTD) for 24 hours and inactivated with 50 mg/ml MMC at 371C for 30 minutes, at an effector:stimulator ratio of 10:1 in RPMI 1640 supplemented with 10% FBS, 50 mM 2-ME, and antibiotics. After 5 days, the splenocytes were collected and used as CTL effector cells. Target cells (YAC-1 and EL4 cells for NK assay; IFN-gstimulated B16BL6 and IFN-g-stimulated EL4 cells for CTL assay) were Eu-labeled and an Eu-release assay was performed as previously described. 30 Cytolytic activity was determined using the following formula: (% of lysis) ¼ [(experimental Eu-release -spontaneous Eurelease)/(maximum Eu-release -spontaneous Eu-release)] Â 100. Spontaneous Eu-release of the target cells was o10% of maximum Eu-release by detergent in all assays.
Results
Gene expression in DCs cotransduced with gp100 and IL-12
We examined the cytopathic effects of AdRGD-IL12 and AdRGD-gp100 on gene transduction into DCs by using the Cell Counting Kit-8 (DOJINDO LABORATORIES, Kumamoto, Japan). At 48 hours posttransduction, viability of DCs transduced with AdRGD-IL12 alone or AdRGD-IL12 plus AdRGD-gp100 remained more than 90% at a vector dose of 200 MOI or less (data not shown). Expression levels of human gp100 and murine IL-12 subunit mRNAs in various transduced DCs were analyzed by RT-PCR at 24 hours after gene transduction (Fig 1) . Human gp100-specific PCR products were detected at the same level only in DCs that were transduced with AdRGD-gp100 alone at 25 MOI (lane 1) or the combination of AdRGD-gp100 at 25 MOI and AdRGD-IL12 at various MOI (lanes 3, 4, and 5). PCR Figure 1 RT-PCR analysis of gp100, IL-12p35, and IL-12p40 in DCs cotransduced with AdRGD-gp100 and AdRGD-IL12. Total RNA was prepared from transduced, LPS-stimulated, or mock DCs, and then RT-PCR was performed as described in the Materials and methods section. The PCR products were electrophoresed through a 3% agarose gel, stained with ethidium bromide, and visualized under ultraviolet light. In order to confirm cytoplasmic expression of human gp100 protein, we performed flow cytometric analysis by the intracellular staining method using HMB50 mAb (Fig  2a) . Under transductional conditions using AdRGDgp100 at 25 MOI, about 70% of DCs could express gp100 protein in their cytoplasm whether or not the DCs were cotransduced individually with AdRGD-IL12 or AdRGD-Luc at 25 MOI. Gene expression intensity (mean fluorescence intensity; MFI) of gp100 in cotransduced DCs was also comparable to that of DCs transduced with AdRGD-gp100 alone. These data clearly demonstrated that the expression level of endogenous antigen transduced with AdRGD was not affected by cotransduction of AdRGD-IL12 in DCs. Likewise, IL-12 secretion levels in DCs transduced with various combinations of AdRGD-gp100 and AdRGD-IL12 were investigated by ELISA (Fig 2b) . MOI-dependent IL-12p70, the biologically active form, and IL12p40 secretion into culture media of DCs cotransduced with AdRGD-gp100 and AdRGD-IL12 was detected at levels equivalent to those of DCs transduced with AdRGD-IL12 alone. Although LPS/DCs could secrete a large quantity of IL12p40 into culture media, secretion of the active form, IL12p70, was maintained at low levels, reflecting the low levels of IL-12p35 mRNA expression in RT-PCR analysis. We first analyzed the expression levels of MHC/costimulatory molecules by flow cytometry in DCs prepared with various combinations of AdRGD-gp100 and AdRGD-IL12 (Fig 3) . In comparison with mock DCs, DCs transduced with AdRGD-gp100 alone exhibited upregulated expression of all tested surface marker molecules, which play critical roles in the sensitization/activation of T cells, as was seen in mature LPS/DCs. This result agreed with our previous report demonstrating that transduction using AdRGD, irrespective of the type of inserted transgene, could enhance the expression of MHC/costimulatory molecules on DCs. 7 In addition, enhanced expression of MHC class I, CD40 and CD86 was observed as a characteristic change in DCs cotransduced with AdRGD-gp100 and AdRGD-IL12 as well as DCs transduced with AdRGD-IL12 alone. As upregulation of these molecules was dependent on MOI of combined AdRGD-IL12, the results suggested that the secreted IL-12 promoted maturation of DCs by an autocrine mechanism.
Next, we compared antigen presentation levels via MHC class I molecules by bioassay using T-T hybridoma, CD8-OVA 1.3 cells, between DCs transduced with various combinations of AdRGD-OVA, AdRGD-IL12, and AdRGD-Luc (Fig 4) . In comparison with DCs transduced with AdRGD-OVA alone, DCs cotransduced with AdRGD-OVA and AdRGD-IL12 showed a slight decrease in IL-2 released from CD8-OVA 1.3 cells by vector dose-increase of combined AdRGD-IL12. The OVA-presentation levels in AdRGD-OVA-transduced DCs were not affected by the addition of exogenous recombinant murine IL-12 into culture media during the antigen-presentation assay (data not shown). In addition, an obvious decline in the OVA-presentation level was observed in DCs cotransduced with AdRGD-OVA and AdRGD-Luc, suggesting that competition may occur during a particular step of the MHC class I Figure 3 Flow cytometric analysis of surface markers in DCs cotransduced with gp100 and IL-12 gene by AdRGD. DCs were cotransduced with AdRGD-gp100 and AdRGD-IL12 at the indicated MOI for 2 hours. DCs treated with 1 mg/ml LPS for 24 hours were used as positive controls for phenotypical DC maturation. At 24 hours after transduction, cells were stained by indirect immunofluorescence using biotinylated mAbs of the indicated specificities (solid histogram). Dotted histograms represent cells stained by phycoerythrin-conjugated streptavidin alone. The data are representative of three independent experiments, and values indicated in the upper part of each panel represent MFI (mean7SD) of flow cytometric analysis. The statistical analysis was carried out by Student's t-test. 
T-cell-stimulating ability of DCs cotransduced with gp100 and IL-12
We performed allogeneic and syngeneic MLR to compare T-cell proliferation-stimulating ability of DCs transduced with AdRGD-gp100 alone or a combination of AdRGDgp100 and AdRGD-IL12. DCs transduced with AdRGDgp100 alone at 25 MOI (gp100(25MOI)/DCs), AdRGD-IL12 alone at 25 MOI (IL12(25MOI)/DCs), AdRGD-Luc alone at 25 MOI (Luc(25MOI)/DCs), or various combinations of AdRGD-gp100 and AdRGD-IL12 (gp100 (25MOI) þ IL12(25MOI)/DCs, gp100(25MOI) þ IL12(12.5 MOI)/DCs, and gp100(25MOI) þ IL12(5MOI)/DCs) could equally stimulate proliferation of allogeneic naive T cells used as responder cells (Fig 5a) . In addition, T-cell proliferation levels in these groups were higher than those not only in mock DCs but also LPS/DCs. These data indicated that DCs transduced by using AdRGD could sufficiently provide proliferative stimuli to T cells through allogeneic interaction of MHC molecules/T-cell receptors and costimulatory signals, regardless of the quantity of IL-12 secreted from DCs. On the other hand, IL12(25-MOI)/DCs, gp100(25MOI) þ IL12(25MOI)/DCs, gp100 (25MOI) þ IL12(12.5MOI)/DCs, and gp100(25MOI) þ IL12(5MOI)/DCs could more strongly stimulate syngeneic naive T-cell proliferation as compared with gp100(25MOI)/DCs or Luc(25MOI)/DCs (Fig 5b) , suggesting that in vitro syngeneic naive T-cell proliferation by DCs cotransduced with AdRGD-gp100 and AdRGD-IL12 was greatly influenced by secreted IL-12 rather than antigen-presentation via MHC molecules. Furthermore, in comparison with gp100(25MOI)/DCs, DCs transduced with AdRGD-IL12 alone or in combination with AdRGD-gp100 could induce considerable proliferation of syngeneic gp100-primed T cells, which were purified from C57BL/6 mice vaccinated beforehand with 10 6 gp100(25MOI)/DCs (Fig 5c) . However, proliferation levels of syngeneic gp100-primed T cells stimulated by DCs transduced with AdRGD-IL12 alone or in combination with AdRGD-gp100 decreased at high responder/ stimulator ratios, and this suppressive effect became remarkable at high AdRGD-IL12 MOI during gene transduction. These observations suggested that excessive IL-12 secreted from transduced DCs might inhibit proliferation or induce cell death in activated T cells.
In addition, we assessed by ELISA the Th1/Th2 cytokine balance in media of syngeneic naive T cells cocultured with various transduced DCs for 5 days at a responder/stimulator ratio of 10 in the presence of 10 U/ ml recombinant murine IL-2 (Table 1) . IL12(25MOI)/ DCs, gp100(25MOI) þ IL12(25MOI)/DCs, gp100(25MOI) þ IL12(12.5MOI)/DCs, and gp100(25MOI) þ IL12(5MOI)/ DCs could markedly enhance Th1-skewing IFN-g secretion from syngeneic naive T cells as compared with mock DCs, whereas only a slight increase in IFN-g levels was observed during cocultivation with gp100(25MOI)/DCs. We confirmed that IFN-g secretion was undetectable in control wells in which only transduced or mock DCs were cultured. On the other hand, secretion of the Th2 cytokines, IL-4 and IL-10, was not detectable in any syngeneic T cells stimulated by transduced or mock DCs. These results suggested that DCs cotransduced with gp100 and IL-12 could more efficiently differentiate sensitized T cells at the Th1-biasing state (the cellular immunity-dominant state), which is required for the induction of efficacious tumor immunity.
Vaccine efficacy of DCs cotransduced with gp100 and IL-12
In order to evaluate the potency of DCs cotransduced with gp100 and IL-12 as vaccine carriers, we investigated protective efficacy against murine B16BL6 melanoma challenge (Fig 6) . C57BL/6 mice received a single intradermal injection of 2 Â 10 5 DCs transduced with various combinations of AdRGD-gp100, AdRGD-IL12, and AdRGD-Luc, and then these mice were inoculated with 2 Â 10 5 B16BL6 melanoma cells at 1 week postimmunization. Obvious growth suppression of the challenging B16BL6 tumor was achieved in mice vaccinated with gp100(25MOI)/DCs, as shown in our previous report, 9 whereas the mice immunized with IL12(25-MOI)/DCs or Luc(25MOI)/DCs showed little or no protective effect as compared with vehicle-injected mice. In addition, a more potent inhibitory effect on tumor growth could be observed in mice after vaccination with gp100(25MOI) þ IL12(5MOI)/DCs than in mice vaccinated with gp100(25MOI)/DCs. However, vaccine efficacy of DCs cotransduced with gp100 and IL-12 tended to diminish with increasing AdRGD-IL12 MOI during gene transduction, and immunization with gp100(25MOI) þ Luc(25MOI)/DCs led to inferior antitumor effects compared to those of the gp100(25MOI)/ DCs group.
Furthermore, we investigated the cytolytic activities of NK cells and CTLs in mice intradermally immunized with DCs cotransduced with gp100 and IL-12 by Eu-release assay. At 1 week after immunization of C57BL/6 mice with various DC vaccines, the splenocytes were used in a cytolytic assay against YAC-1 and EL4 cells, and were restimulated in vitro with inactivated B16BL6 cells, which were treated with recombinant murine IFN-g to promote the expression of their MHC class I molecules, for CTL expansion. As shown in Figure 7a , the splenic cytolytic activity against YAC-1 cells markedly increased after immunization with gp100(25MOI) þ IL12(25MOI)/DCs as well as IL12(25MOI)/DCs, whereas EL4 cells were not injured by splenocytes prepared from any groups. Effector cells from mice immunized with gp100(25MOI) þ IL12(5MOI)/DCs exhibited equivalent NK activity to those from mice immunized with gp100(25MOI)/DCs. These data indicated that the nonspecific NK activity involved in the anti-B16BL6 melanoma response was enhanced with the increase in IL-12 secretion from the administered DC vaccine. On the other hand, the cytolytic effects on B16BL6 cells by in vitro restimulated effector cells was promoted in mice immunized with gp100(25MOI) þ IL12(5MOI)/DCs as compared with mice immunized with gp100(25MOI)/DCs (Fig 7b) . This cytolytic activity was caused by B16BL6-specific CTLs because the effector cells prepared from Data are expressed as mean7SD of three independent cultures. group. However, consistent with the protective effect against B16BL6 tumor challenge, mice vaccinated with gp100(25MOI) þ IL12(25MOI)/DCs showed lower B16BL6-specific CTL activity than mice immunized with gp100(25MOI)/DCs. Therefore, immunization with DCs genetically modified to express simultaneously gp100 and IL-12 exhibited duplicity for the host's immune response in our experimental model. That is, as compared with DCs transduced with AdRGD-gp100 alone, DCs cotransduced with AdRGD-IL12 at a relatively low ratio to AdRGDgp100 were equal in inducibility of NK activity, but could more efficiently induce anti-B16BL6 tumor effects and antigen-specific CTL activity. In contrast, DCs combined with a high dose of AdRGD-IL12 during gene transduction could enhance NK activity, but attenuated B16BL6-protective efficacy and CTL activity.
Discussion
Since DCs are the most potent APCs and are uniquely capable of presenting novel antigens to naive T cells to initiate and modulate immune responses, 1,2 various DCbased vaccines for use in immune intervention strategies against cancer have been designed and studied in many research organizations. Antitumor CTLs play a central role in the tumor-specific immune response, and the efficient priming and subsequent activation of antitumor CTLs requires the processing and presentation of TAAs as peptide fragments in the context of appropriate MHC class I molecules by APCs. 31 In addition, a Th1-biased cytokine balance is desirable for sensitization of CTLs specific for TAA by APCs. IL-12 is the key factor that skews the immune balance toward a Th1 response and that can promote a switch from an established Th2 to a Th1 response. 32, 33 In fact, potent antitumor effects of DCs genetically engineered with IL-12 have been demonstrated in several murine models by vaccination using TAA-derived peptide pulsed DCs or intratumoral injection using unpulsed DCs. [34] [35] [36] Therefore, we believe that, as compared with DCs delivered with TAA gene alone, DCs genetically manipulated to express simultaneously TAA and IL-12 might be a promising vaccine carrier Figure 7 NK (a) and B16BL6-specific CTL (b) activity in mice immunized with DCs cotransduced with gp100 and IL-12 gene by AdRGD. DCs were transduced with the indicated combinations of AdRGD-gp100 and AdRGD-IL12 at the indicated MOI for 2 hours. Transduced or mock DCs were vaccinated once intradermally into C57BL/6 mice at 2 Â 10 5 cells. At 1 week after immunization, nonadherent splenocytes were prepared from these mice, and directly used in cytolytic assays against YAC-1 and EL-4 cells (a). In addition, the isolated splenocytes were restimulated in vitro for 5 days with IFN-g-stimulated and MMC-inactivated B16BL6 cells. A cytolytic assay using the restimulated splenocytes was performed against IFN-g-stimulated B16BL6 and EL4 cells (b). Each point represents the mean7SE of four independent cultures from four individual mice. A vector system, which can effectively deliver a foreign gene to DCs, is required to create a genetically modified DC vaccine having a potential to improve the efficacy of DC-based immunotherapy. We have demonstrated that AdRGD enabled highly efficient gene transduction into murine and human DCs because of the targeting of avintegrin by the RGD sequence inserted at the HI-loop in their fiber knob. [6] [7] [8] [9] When mouse bone marrow-derived DCs were cotransduced with AdRGD-gp100 and AdRGD-IL12, their expression of gp100 and IL-12 was comparable to that in DCs transduced with each AdRGD alone (Figs 1 and 2) . IL-12 secreted from these DCs is biologically active because direct intratumoral injection of AdRGD-IL12, used in the present study and whose expression cassette was designed to be transcribed from IL-12p35 cDNA to the internal ribosome entry site sequence to IL-12p40 cDNA under the control of the cytomegalovirus promoter, could induce tumor regression based on promotion of tumor immunity in melanomabearing mice. 37 RT-PCR analysis (Fig 1) suggested that LPS-driven maturation or irrelevant AdRGD transduction could moderately enhance expression of the IL-12p40 subunit mRNA in DCs, but not IL-12p35 subunit mRNA. Several reports have demonstrated that the production of the two IL-12 subunits is regulated by different mechanisms, mainly at the level of mRNA expression, and that the level of bioactive IL-12p70 production in APCs in response to LPS and cytokines is determined by the level of IL-12p35 expression. 38, 39 Therefore, DCs cannot attain sufficient IL-12p70 productivity, which is based on enhancement of endogenous gene expression of the two subunits, via a maturation signal from LPS or AdRGD transduction alone. Taken together, our results demonstrated that DCs cotransduced with AdRGD-gp100 and AdRGD-IL12 could simultaneously express gp100 and IL-12 at levels equal to DCs transduced with each vector alone, indicating that DCs can obtain several additional functions by using a combination of AdRGDs carrying different genes.
Full analysis and understanding of immunological characteristics of DC vaccine are imperative for the development of DC-based immunotherapy because the polarity of the immune response is greatly influenced by the activated state of DCs during T-cell sensitization. Flow cytometric analysis indicated that the expression of MHC class I/II, CD40, CD80, and CD86 molecules was enhanced only by AdRGD-transduction, and that DCs transduced with the IL-12 gene exhibited considerable upregulation of MHC class I, CD40, and CD86 molecules on their surface in response to autocrine effects of secreted IL-12 as compared with DCs transduced with AdRGDgp100 alone (Fig 3) . On the other hand, DCs cotransduced with OVA and IL-12 by AdRGDs exhibited lower OVA-presentation levels via MHC class I molecules than DCs transduced with AdRGD-OVA alone (Fig 4) , although the cytoplasmic expression of endogenous antigen introduced into DCs was not affected by the combination with other AdRGDs (Fig 2a) . In addition, OVA-presentation levels in DCs transduced with AdRGD-OVA were markedly decreased by combination with AdRGD-Luc, which expresses luciferase as another endogenous antigen (Fig 4) . These inconsistent results suggested that processing machineries in the MHC class Ipresentation pathway may compete with multiple proteins transduced by the combination of AdRGDs, and that localization characteristics, such as cytoplasmic accumulation, extracellular secretion, and plasma membranespecific localization, of other proteins should be considered during the preparation of DCs expressing TAA and other functional proteins by cotransduction with multiple AdRGDs in an attempt to maintain sufficient TAA-presenting capacity. With regard to T-cell-stimulating ability, DCs cotransduced with gp100 and IL-12 could more effectively enhance proliferation of syngeneic naive and gp100-primed T cells than DCs transduced with gp100 alone, although allogeneic T-cell proliferation did not differ between the two types of transduced DCs ( Fig  5) . Furthermore, we could detect considerable IFN-g secretion from syngeneic naive T cells stimulated by DCs cotransduced with gp100 and IL-12 (Table 1) , as expected. These data from in vitro immunological analysis suggested that DCs cotransduced with TAA and IL-12 using AdRGD can function as useful vaccine carriers possessing TAA-presentation ability, sufficient T-cellstimulating ability, and Th1-driving ability in vivo.
We attempted to compare vaccine efficacy of DCs genetically modified with various combinations of AdRGD-gp100, AdRGD-IL12, and AdRGD-Luc using the murine B16BL6 melanoma model. Although mice vaccinated with gp100(25MOI) þ IL12(5MOI)/DCs exhibited more effective suppression of B16BL6 tumor growth and efficient induction of B16BL6-specific CTLs than those vaccinated with gp100(25MOI)/DCs, vaccine efficacy of cotransduced DCs diminished with increasing combined AdRGD-IL12 MOI during gene transduction, contrary to our expectation (Figs 6 and 7) . We speculated that this adverse effect might be caused by a decrease in antigen presentation in DCs by coexpression of TAA and IL-12 as shown in Figure 4 , because the anti-B16BL6 effect of gp100(25MOI) þ Luc(25MOI)/DCs was obviously inferior to that by gp100(25MOI)/DCs. An alternative explanation for the negative effect of AdRGD-IL12-cotransduction includes an immunosuppressive effect of excess IL-12 on the host's immune cells. Several studies have demonstrated that IL-12 inhibits cellmediated immune responses, such as clonal expansion of CTLs, in a dose-dependent manner through IFN-gmediated nitric oxide production by macrophages in the murine models. [40] [41] [42] [43] The in vivo bimodal effect of DCs cotransduced with gp100 and IL-12 in our model might involve immunosuppression based on nitric oxide, because DCs transduced with AdRGD-IL12 could drastically enhance IFN-g secretion from syngeneic naive T cells in MLR (Table 1 ). In addition, Piccioli et al 44 reported that an in vitro interaction between activated NK cells and DCs at high NK/DC ratios resulted in inhibition of DC functions due to potent killing by NK cells, whereas this interaction at low NK/DC ratios led to drastic increases in DC cytokine production. Therefore, a remarkable increase in NK activity in mice that were vaccinated with gp100(25MOI) þ IL12(25MOI)/DCs, as shown in Figure 7 , might suppress the induction of the B16BL6-specific immune response by the administered DC vaccine.
To date, vaccine efficacy of DCs cotransduced with TAA and IL-12 has not been fully clarified because both positive 45 and negative 46 effects of simultaneous expression of IL-12 in DC vaccine have been reported. Based on the results of the present study, we concluded that determination of the specific vector dose capable of optimizing both TAA-presentation levels and IL-12-secretion levels in DC vaccine is essential for improving antitumor efficacy based on active biasing of the immune response toward a cellular immunity dominated state.
Abbreviations 2-ME, 2-mercaptoethanol; AdRGD, RGD fiber-mutant adenovirus vector; APC, antigen-presenting cell; BrdU, 5-bromo-2 0 -deoxyuridine; CTL, cytotoxic T lymphocyte; DC, dendritic cell; Eu, europium; FBS, fetal bovine serum; GM-CSF, granulocyte/macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; mAb, monoclonal antibody; MHC, major histocompatibility complex; MLR, mixed leukocyte reaction; MMC, mitomycin C; MOI, multiplicity of infection; NK, natural killer; OVA, ovalbumin; PBS, phosphate-buffered saline; RT-PCR, reverse transcription-polymerase chain reaction; TAA, tumor-associated antigen; Th, helper T cell.
